Karim Fizazi

Prof Karim Fizazi, an academic oncologist focused on genitourinary cancers, and Dr Daniel George, a prostate cancer clinical investigator at Duke, discuss AKT inhibition and PTEN deficiency in metastatic prostate cancer. They cover biomarker testing methods, rationale for AKT targeting, trial results including CAPItello-281, toxicity management, timing of therapy, and clinical integration of AKT inhibitors.